141 related articles for article (PubMed ID: 28589183)
41. Novel abdominal approach for dissection of advanced type II/III adenocarcinoma of the esophagogastric junction: a new surgical option.
Hu C; Zhu HT; Xu ZY; Yu JF; Du YA; Huang L; Yu PF; Wang LJ; Cheng XD
J Int Med Res; 2019 Jan; 47(1):398-410. PubMed ID: 30296865
[TBL] [Abstract][Full Text] [Related]
42. Treatment approaches to esophagogastric junction tumors.
Kurokawa Y; Sasako M; Doki Y
Dig Surg; 2013; 30(2):169-73. PubMed ID: 23867594
[TBL] [Abstract][Full Text] [Related]
43. Outcomes of Abdominal Total Gastrectomy for Type II and III Gastroesophageal Junction Tumors: Single Center's Experience in Korea.
Kim KT; Jeong O; Jung MR; Ryu SY; Park YK
J Gastric Cancer; 2012 Mar; 12(1):36-42. PubMed ID: 22500262
[TBL] [Abstract][Full Text] [Related]
44. Worldwide trends in surgical techniques in the treatment of esophageal and gastroesophageal junction cancer.
Haverkamp L; Seesing MF; Ruurda JP; Boone J; V Hillegersberg R
Dis Esophagus; 2017 Jan; 30(1):1-7. PubMed ID: 27001442
[TBL] [Abstract][Full Text] [Related]
45. Long-Term Efficacy of Neoadjuvant Concurrent Chemoradiotherapy for Potentially Resectable Advanced Siewert Type II and III Adenocarcinomas of the Esophagogastric Junction.
Tian Y; Wang J; Qiao X; Zhang J; Li Y; Fan L; Zhang Z; Zhao X; Tan B; Wang D; Yang P; Zhao Q
Front Oncol; 2021; 11():756440. PubMed ID: 34858829
[TBL] [Abstract][Full Text] [Related]
46. [Adenocarcinoma of the esophagogastric junction: retrospective analysis of 39 patients].
Butte JM; Becker F; Visscher A; Waugh E; Meneses M; Court I; Parada H; DE LA Fuente H
Rev Med Chil; 2010 Jan; 138(1):53-60. PubMed ID: 20361151
[TBL] [Abstract][Full Text] [Related]
47. Comparison of prognostic compatibility between seventh AJCC/TNM of the esophagus and 14th JCGC staging systems in Siewert type II adenocarcinoma.
Kawaguchi T; Komatsu S; Ichikawa D; Kubota T; Okamoto K; Shiozaki A; Fujiwara H; Konishi H; Morimura R; Murayama Y; Kuriu Y; Ikoma H; Nakanishi M; Sakakura C; Otsuji E
Anticancer Res; 2013 Aug; 33(8):3461-5. PubMed ID: 23898120
[TBL] [Abstract][Full Text] [Related]
48. Surgical Treatment of Gastroesophageal Junction Cancer.
Hashimoto T; Kurokawa Y; Mori M; Doki Y
J Gastric Cancer; 2018 Sep; 18(3):209-217. PubMed ID: 30275998
[TBL] [Abstract][Full Text] [Related]
49. [Clinical and pathological prognostic factors for cancers of the esophagogastric junction].
Schmidt SC; Schlechtweg N; Veltzke-Schlieker W; Thuss-Patience P; Pratschke J; Neuhaus P; Schumacher G
Zentralbl Chir; 2009 Sep; 134(5):455-61. PubMed ID: 19757346
[TBL] [Abstract][Full Text] [Related]
50. 101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy.
Mizrak Kaya D; Wang X; Harada K; Blum Murphy MA; Das P; Minsky BD; Estrella JS; Lin Q; Amlashi FG; Lee JH; Weston B; Bhutani MS; Matamoros A; Sagebiel T; Wu CC; Rogers JE; Thomas I; Maru DM; Skinner HD; Badgwell BD; Hofstetter WL; Ajani JA
Oncology; 2017; 93(4):243-248. PubMed ID: 28683449
[TBL] [Abstract][Full Text] [Related]
51. Optimal treatment for Siewert type II and III adenocarcinoma of the esophagogastric junction: A retrospective cohort study with long-term follow-up.
Hosoda K; Yamashita K; Moriya H; Mieno H; Watanabe M
World J Gastroenterol; 2017 Apr; 23(15):2723-2730. PubMed ID: 28487609
[TBL] [Abstract][Full Text] [Related]
52. Treatment of esophago-gastric junction adenocarcinoma.
de Manzoni G; Zanoni A; Giacopuzzi S
Ann Ital Chir; 2012; 83(3):208-14. PubMed ID: 22595732
[TBL] [Abstract][Full Text] [Related]
53. Is adenocarcinoma of the esophagogastric junction different between Japan and western countries? The incidence and clinicopathological features at a Japanese high-volume cancer center.
Hasegawa S; Yoshikawa T; Cho H; Tsuburaya A; Kobayashi O
World J Surg; 2009 Jan; 33(1):95-103. PubMed ID: 18958523
[TBL] [Abstract][Full Text] [Related]
54. Novel Histologic Categorization Based on Lauren Histotypes Conveys Prognostic Information for Gastroesophageal Junction Cancers-Analysis from a Large Single Center Cohort in Germany.
Schirren R; Novotny A; Slotta-Huspenina J; Friess H; Reim D
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804009
[TBL] [Abstract][Full Text] [Related]
55. Interaction of splenectomy and perioperative blood transfusions on prognosis of patients with proximal gastric and gastroesophageal junction cancer.
Weitz J; D'Angelica M; Gonen M; Klimstra D; Coit DG; Brennan MF; Karpeh MS
J Clin Oncol; 2003 Dec; 21(24):4597-603. PubMed ID: 14673048
[TBL] [Abstract][Full Text] [Related]
56. Feasibility of laparoscopic total gastrectomy for advanced Siewert type Ⅱ and type Ⅲ esophagogastric junction carcinoma: A propensity score-matched case-control study.
Zhao Y; Zhang J; Yang D; Tang Z; Wang Q
Asian J Surg; 2019 Aug; 42(8):805-813. PubMed ID: 30685144
[TBL] [Abstract][Full Text] [Related]
57. Indication for endoscopic treatment based on the risk of lymph node metastasis in patients with Siewert type II/III early gastric cancer.
Pyo JH; Lee H; Min YW; Min BH; Lee JH; Kim KM; Yoo H; Ahn S; Kim JJ
Gastric Cancer; 2018 Jul; 21(4):672-679. PubMed ID: 29243195
[TBL] [Abstract][Full Text] [Related]
58. [Surgical treatment of gasto-esophageal junction adenocarcinoma: long-term results of a single Italian centre].
Pedrazzani C; Pasini F; Giacopuzzi S; Bernini M; Ruzzenente A; Festini M; Tomasi I; Cristadoro L; de Manzoni G
G Chir; 2004 Oct; 25(10):325-33. PubMed ID: 15756954
[TBL] [Abstract][Full Text] [Related]
59. Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction.
Zhao Q; Li Y; Wang J; Zhang J; Qiao X; Tan B; Tian Y; Shi G; Xu Q; Li R; Liu Y; Yang P
Am J Med Sci; 2015 Jun; 349(6):472-6. PubMed ID: 25996101
[TBL] [Abstract][Full Text] [Related]
60. Benefit of neoadjuvant chemotherapy for Siewert type II esophagogastric junction adenocarcinoma.
Hosoda K; Yamashita K; Katada N; Moriya H; Mieno H; Sakuramoto S; Kikuchi S; Watanabe M
Anticancer Res; 2015 Jan; 35(1):419-25. PubMed ID: 25550582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
